Jcog1113

Author: agop

August undefined, 2024

Web18 giu 2024 · JCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). However, poor renal function often results in high toxicity of S-1. Therefore, we examined whether GS ca … Web11 giu 2024 · Based on these results, a phase III trial to confirm the non-inferiority of GS to GC was conducted (JCOG1113, FUGA-BT, UMIN000010667, primary endpoint: overall survival). The result of this study was presented at …

Comparison of clinical features by primary sites in patients with ...

Web29 gen 2024 · 368 Background: JCOG1113 is a randomized phase III trial to evaluate gemcitabine (GEM) plus S-1 (GS) versus GEM plus cisplatin (GC) regarding overall survival (OS) for advanced biliary tract cancer (BTC) (UMIN000001685) and the non-inferiority of GS was demonstrated. It is necessary to consider renal function using cisplatin or S-1 … Web10 mag 2024 · Gemcitabine combined with platinum/fluorouracil drugs is the standard first-line treatment for advanced biliary tract cancers (BTCs). We explored the safety and efficacy of toripalimab plus gemcitabine and S-1 (GS) as the first-line treatment for advanced BTCs. At a one-sided significance level of 0.025, a total of 50 patients could provide 80% power … jim beam fire helmet decanter

OPEN The clinical outcomes of combination chemotherapy analysis of JCOG1113

WebNational Center for Biotechnology Information WebA Phase II selection design trial was conducted to identify the most promising regimen for comparison with standard therapy in chemo-naive patients with unresectable or recurrent biliary tract cancer (JCOG0805). Gemcitabine plus S-1 therapy showed better efficacy than S-1 monotherapy with acceptable … WebA phase II study, JCOG0805 showed that gemcitabine plus S-1 was more promising than S-1 alone in ABTC, and a recently phase III JCOG1113 (FUGA-BT) showed gemcitabine plus S-1 (GS) is non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) benefit. install intel rapid storage technology

Multicentre, phase II study of gemcitabine and S‐1 in patients with ...

AB026. S5A-2. The role of TS-1 in cholangiocarcinoma

Web18 giu 2024 · JCOG1113 is a randomized phase III trial in patients with advanced biliary tract cancers (BTCs) (UMIN000001685), and gemcitabine plus S-1 (GS) was not inferior to gemcitabine plus cisplatin (GC). Web30 set 2024 · In 2024, the JCOG1113 study indicated that GEM plus S-1 (GEM/S-1) was not inferior in treating advanced biliary tract carcinoma, and it had an acceptable toxicity profile compared to GEM/CDDP in a ... install intel omnipath testsWeb1 giu 2024 · 4014 Background: Gemcitabine (GEM) plus cisplatin (GC) is the standard of care for advanced biliary tract cancer (BTC). However, GC is considered to be toxic because of nausea, vomiting, and appetite loss, and inconvenient due to requiring hydration before and after administration. GEM plus S-1 (GS) was reported to be promising with … jim beam fireball whiskey

"WebThe oral fluoropyrimidine, S-1, combined with or without gemcitabine is considered to be a promising agent for treating advanced biliary tract cancer; gemcitabine plus cisplatin is the current standard regimen. This randomized phase II trial was designed to evaluate the safety and efficacy of two re … " - Jcog1113

Jcog1113

Web19 gen 2024 · In the FUGA-BT trial (JCOG1113), gemcitabine plus S-1 (GS) showed non-inferiority to gemcitabine plus cisplatin (GC) in overall survival (OS) with good tolerance for patients with advanced biliary tract cancer (BTC). We performed a subgroup analysis focused on the elderly cohort of this trial. All 3 … WebDISCLAIMER: The appearance of hyperlinks does not constitute endorsement by the 413th Flight Test Group, the U.S. Air Force Reserve, or the Department of Defense, of the external Web site, or the information, products or services contained therein.

Did you know?

WebIn JCOG1113, GS showed non-inferiority to GC in overall survival (OS) with good tolerance (median OS: 13.4 months with GC and 15.1 months with GS, hazard ratio 0.945; 90% condence interval 0.78 ... WebIn JCOG1113, GS showed non-inferiority to GC in overall survival (OS) with good tolerance (median OS: 13.4 months with GC and 15.1 months with GS, hazard ratio 0.945; 90% condence interval 0.78 ...

WebBackground: JCOG1113 (UMIN000001685) is a randomized phase III trial in patients (pts) with advanced biliary tract cancers (BTCs) that shows the non-inferiority of gemcitabine plus S-1 (GS) to gemcitabine plus cisplatin (GC) regarding overall survival (OS). Previous reports suggest that a history of major hepatectomy (MH) may affect dose intensity and adverse … Web胆道癌 FUGA‐BT（JCOG1113） Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial. Morizane C, et al. …

Web1 dic 2024 · Introduction. Biliary tract cancers (BTCs), including cancers of the intrahepatic bile duct (IHBD), extrahepatic bile duct (EHBD), gallbladder (GB), and ampulla of Vater (AV), are relatively rare [1].BTC is often diagnosed at an advanced stage, and early postoperative recurrence is frequent, even in patients with resectable disease [2].The prognoses of … Web22 gen 2024 · January 20th 2024. Results from the phase 2 Talem trial, presented at the 2024 Gastrointestinal Cancers Symposium, showed the promising signs of efficacy, anti-tumor activity, and tolerable adverse events when combining blank-microsphere transarterial chemoembolization with lenvatinib and sequential microwave ablation for patients with …

WebDisclaimer: These codes may not be the most recent version.Georgia may have more current or accurate information. We make no warranties or guarantees about the accuracy, completeness, or adequacy of the information contained on this site or the information linked to on the state site.

Web13 lug 2010 · The clinical outcomes of combination chemotherapy in elderly patients with advanced biliary tract cancer: an exploratory analysis of JCOG1113 19 January 2024 Ikuhiro Yamada, Chigusa Morizane, … jim beam fire truckWebThe JCOG1113 study suggested that gemcitabine plus S-1 (GS) had noninferior median overall survival and comparable incidence of significant neutropenia as compared to GC treatments. This study evaluates the efficacy and safety of a modified GS regimen. install intel r processor graphics windows 10WebJCOG1113 進行胆道癌を対象としたゲムシタビン+シスプラチン併用療法（GC療法）とゲムシタビン+S-1併用療法（GS療法）の第III相比較試験実施計画書ver. 1.2 Randomized phase III study of gemcitabine plus S-1 combination therapy versus install intel r uhd graphics 30.0.101.1404Web19 gen 2024 · Between May 8, 2013 and March 4, 2016, a total of 354 patients were enrolled to JCOG1113; 175 were assigned to the GC arm and 179 to the GS arm. For this subgroup analysis to investigate the influence of age, all registered patients of JCOG1113 were stratified by age; < 75 (non-elderly group) and ≥ 75 years (elderly group). jim beam fire truck bottleWeb19 gen 2024 · Patient characteristics. Of all registered 354 patients in JCOG1113, 60 patients aged ≥ 75 years were classified into the elderly group (20 in GC arm and 40 in GS arm), and 294 patients aged ... jim beam for the love of a horse decanterWebCC-13 JOINT LEGAL CUSTODY ATTACHMENT TO Petition Response Request for Order Responsive Declaration to Request for Order Stipulation and Order for Custody and/or Visitation of Children Findings and Order After Hearing or Judgment install intel optane memory in laptopWebJCOG1113 (UMIN000010667) showed the non-inferiority of gemcitabine plus S-1 to gemcitabine plus cisplatin in terms of overall survival (OS) in patients (pts) with advanced BTCs. We aimed to compare clinical features among the primary sites of BTCs using JCOG1113 data. Methods: Among the 354 pts enrolled in JCOG1113, 352 pts were … install intel smart sound technology driver